Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates. Turning to some newly published research, we discuss the early results of a first-in-human clinical trial that is testing a dual vaccine against Lassa fever and rabies, a CRISPR system engineered to selectively trigger cancer cell death by chromatin shredding, and a novel mRNA delivery platform for delivering gene therapies starting with Duchenne muscular dystrophy.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO
By Alex Philippidis, GEN Edge, June 14, 2026

Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
By Alex Philippidis, GEN Edge, June 16, 2026

First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data
GEN, June 9, 2026

CRISPR Shreds Undruggable Cancer Cells with Precision
By Fay Lin, PhD, GEN Edge, June 8, 2026

New mRNA Delivery Platform Restores Muscle Function in DMD Models
GEN, June 11, 2026

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD

The post Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine appeared first on GEN - Genetic Engineering and Biotechnology News.